Live
FierceBiotechHow data-driven diagnostic lab services drive precise clinical trial enrollmentFierceBiotechRedefining what success looks like in PSC: The evolution of clinical trial endpointsBioPharma DiveModerna flu vaccine wins unanimous support from FDA panelFierceBiotechModerna’s flu candidate sails through FDA advisory committee in unanimous votesEndpoints NewsFDA vaccine advisors unanimously support Moderna's flu shotScienceWolves are reconquering Europe. Can people learn to live with them?Clinical OMICsPakistan’s Massive Genetic Database Reveals Millions of Unique VariantsClinical OMICsFirst Novel Antifungal for Aspergillus in 20 Years Succeeds in Phase IIIBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-June 18, 2026Endpoints NewsTreasury weighs screening investments in China biotechBioWorldIn the clinic for June 18, 2026
eLife Jan 23, 2026

HIV-specific CD8+ T-cell proliferative response 24 weeks after early antiretroviral therapy initiation is associated with the subsequent reduction in the viral reservoir

HIV-specific CD8+ T-cell proliferative response 24 weeks after early antiretroviral therapy initiation is associated with the subsequent reduction in the viral...

Body unavailable. Use the original source.